About us

Who we are

A multidisciplinary team

Aenitis, a CNRS and ESPCI Paris spin-off founded by Emmanuel VINCENT, Mauricio HOYOS, and Jean-Luc AIDER, unites scientific expertise with industrial vision.

Our multidisciplinary team is on a mission to make cell handling gentler, and more efficient while ensuring top-quality results at every step.

Aenitis données marché

Our commitment

Setting new standards

Setting new paths and standards for biomanufacturing; an industry challenged by scalability, efficiency, and cost because every patient deserves access to tomorrow’s therapies.

Biomanufacturing is a strategic driver of modern healthcare, especially as 60% of today’s drug candidates are biomedicines. It powers advanced therapies such as cell and gene treatments, offering hope for rare or complex diseases where conventional medicine falls short.

Challenges

  • High risk of cell stress and contamination
    Excessive manual handling can compromise sterility, induce cell loss and may damage sensitive cells.
  • Ensuring regulatory compliance and patient safety
    The production of advanced biologics increasingly requires strict regulatory standards to guarantee patient safety. Aenitis anticipates these needs by using high-quality materials in its consumables and performing rigorous biocompatibility and cytotoxicity testing, ensuring that every process step meets the highest safety and quality requirements.
  • Cell fragility
    Some cell types are sensitive and may lose viability or functionality due to mechanical stress, lack of oxygen, or suboptimal nutrient conditions.
  • Reducing cell loss and associated costs
    Handling sensitive cells, such as stem cells, often results in significant losses or unwanted activation during processing; a costly issue for high-value biologics. Aenitis’ gentle, contactless acoustic technology minimizes these losses, preserving cell quality while improving overall process efficiency.
  • Difficulty isolating rare or complex cells
    Certain target cells, such as lymphocytes, are physically similar to other cell types, making precise separation challenging.

What we do

Innnovative platform

To overcome biomanufacturing challenges, Aenitis has developed an innovative acoustic system that opens new possibilities for cell processing by being:

  • Non-invasive and contact-free, preserving delicate cell integrity
  • Continuous-flow, enabling seamless scale-up from lab to commercial volumes
  • Reducing manual handling to streamline workflows and limit variability
  • GMP-ready, meeting strict regulatory and quality standards
  • Label-free for most applications, with optional use of acoustic beads

Our thechnology enables

  • Effortless scalability without quality loss, from small batches to large production runs
  • Precise cell manipulation to maintain viability and function
  • Protection of fragile cells by minimizing mechanical stress
  • Cost and waste reduction through streamlined workflows and shorter lead times

This modular platform addresses key industry bottlenecks and redefines biomanufacturing standards; not only for cell and gene therapies, but also for a wide range of advanced biologics.

Our mission is to enable reliable, scalable production of advanced therapies, ensuring broader patient access, especially for rare and complex diseases.

Technology Positionning in
Cell and Gene therapy processing

key functional indicators

Centrifugation

Counterflow centrifugation

Filters

Magnetic handling

Millifluid acoustic handling

Volumes processed

IMPORTANT
>500mL

IMPORTANT
>500mL
Nota: The centrifugation chamber is 10 mL.

LIMITED
<300ml on average according to cell quantity

LIMITED
<300mL

IMPORTANT
>500mL

Flow/Time

VERY IMPORTANT
Up to several L/min.

IMPORTANT
up to 160mL/min max.

LIMITED

IMPORTANT
2 to 150mL/min. on average

IMPORTANT
Up to 100mL per min.

amount of cells per ml

IMPORTANT
no theoretical limit

AVERAGE
5 x 106 to 5 x 108 cells per mL

LIMITED
Varies by porosity

LIMITED
1 to 10 x 106 cells per mL.

IMPORTANT
Up to 109 cells per mL

Selectivity/Specifity of selection

AVERAGE
Limit to generated layers

IMPORTANT
Nota: limit of possible uses

AVERAGE
imitated to the porosity of filters

VERY IMPORTANT
Antibodies are very specific

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

VERY IMPORTANT
with acoustic beads systems

Machinal stress on the cells

IMPORTANT
Centrifugal force up to 5000 g

IMPORTANT
Shear effects + centrifugal force up to 3000 g

AVERAGE
Contact with the cells

LOW
Limited impact of antibodies

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

Cost

LOW

IMPORTANT

LOW

VERY IMPORTANT

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

Versatility

IMPORTANT

LIMITED

LIMITED

REASONABLE

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

Technology Positionning in
Cell and Gene therapy processing

Centrifugation

Counterflow
Centrifugation

Filters

Magnetic handling

Millifluid acoustic handling

Volumes processed

>500mL
Nota: The centrifugation chamber is 10mL
<300mL on avergae according to cell quantity
<300mL
>500mL

Flow/Time

Up to several L/min
Up to 160mL/min max
Texte
2 to 150mL/min on average
Up to 100mL per min

Amount of cells per mL

IMPORTANT
No theoretical limit

AVERAGE
5×106 to 5×108 cells per mL

LIMITED
Varies by porosity

LIMITED
1 to 10×106 cells per mL

IMPORTANT
Up to 109 cells per mL

Selectivity/Specifity of selection

AVERAGE
Limit to generated layers

IMPORTANT
Nota: limit of possible uses

AVERAGE
Limitated to the porosity of filters

VERY IMPORTANT
Antiboodies are very specific

IMPORTANT
Acoustic forces coupled with milifluid design offer improved selectivity versus centrifugation

VERY IMPORTANT
With acoustic beads systems

Machinal stress on the cells

IMPORTANT
Centrifugal force up to 5000g

IMPORTANT
Shear effects + centrifugal force up to 3000g

AVERAGE
Contact with the cells

LOW
Limited impact of antibodies

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

Cost

LOW

IMPORTANT

LOW

VERY IMPORTANT

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

Versatility

IMPORTANT

LIMITED

LIMITED

REASONABLE

IMPORTANT
Acoustic forces coupled with milifluidic design offer improved selectivity versus centrifugation

Management team

EVweb
Emmanuel Vincent
Co-founder and Chief Executive Officer

After obtaining a Master in Cellular and Molecular Biology from the University of Nantes (FR) and the University of Sussex (UK), Emmanuel completed his training with a Specialized Master in Management of Biotechnology Companies in Grenoble Ecole de Management (Grenoble Business School).

He also holds an Executive Master of Business and Administration (eMBA) from the University Paris-Dauphine (FR) and the University of Quebec in Montreal (CA). Emmanuel has a strong professional experience in international business development, in analysis of business models and in consolidation of strategic intelligence in the biotechnology sector. He also has a good knowledge of the biotech ecosystem in France, and of the major world bioclusters.

Read more
Jacky
Jacky Harrouet
Chief Financial Officer

Jacky holds a degree of the DESCF (Graduate degree in accounting and financial studies) and began his career in an audit and financial expertise firm during 4 years. For nearly 20 years, Jacky holds positions in Finance (CFO) and General Management (COO/CEO) in companies with high development potential (Startups).

The quality of the relations that Jacky has forged with his investors, led him in addition to advising them to regularly represent them on the management and/or strategic committees of other companies that they finance.

His experience and analytical skills allow him to combine the management of day-to-day imperatives with the medium- and long-term objectives of a company with high development potential.

Read more
Skander Rollet
Chef Development & Production Officer

Skander holds a Master’s degree in mechanical engineering from Arts & Métiers ParisTech.

Skander worked in the aerospace industry for 12 years, holding quality, continuous improvement and production management roles.

Just before joining Aenitis, he worked for 3 years at Pall Life Science on the development and industrialization of Single-Use components for biotechnological applications.

Read more
Stéphane Ploquin
Chief Quality & Regulatory Affairs Officier

Graduated Pharm. D. Industry, and specialized in Quality and Bio-products, Stephan Ploquin is actively collaborating, updating and creating Quality Management Sytems in the Pharmaceutical and Medical Industry.

He contributed to the extension of worldwide applications for several different brands of products for more than 20 years.

Moreover, his broad experience in both Pharmaceutical products and Medical Devices, acting within Biologicals and Combined Products

are now one of his center of interest. From International Clinical, Regulatory and Quality Director, but also QP – Responsible

Pharmacist and consultant, to date he brings his expertise up to development and set up of innovative solutions

Read more
Vincent Baudouin
Research Director, PhD

Vincent obtained his PhD in Cellular and Molecular biology from the Université Paris-Cité. During his PhD he highlighted common mechanisms and therapeutics targets in neurodegenerative diseases.

He also discovered new molecules and molecular mechanisms to fight inflammation. Then, he joined Institut Pasteur for a Post doctorate fellowship on Chlamydia Trachomatis infection focusing on the identification of antibody trafficking and their effect on chlamydia infection. Vincent has a great experience in cellular and molecular biology and joined Aenitis in 2023 to work on the biological aspect of our projects.

Read more

Strategic advisory board

EVweb
Emmanuel Vincent
Co-founder and Chief Executive Officer

After obtaining a Master in Cellular and Molecular Biology from the University of Nantes (FR) and the University of Sussex (UK), Emmanuel completed his training with a Specialized Master in Management of Biotechnology Companies in Grenoble Ecole de Management (Grenoble Business School).

He also holds an Executive Master of Business and Administration (eMBA) from the University Paris-Dauphine (FR) and the University of Quebec in Montreal (CA). Emmanuel has a strong professional experience in international business development, in analysis of business models and in consolidation of strategic intelligence in the biotechnology sector. He also has a good knowledge of the biotech ecosystem in France, and of the major world bioclusters.

Read more
JLAweb
Jean-Luc Aider
Co-founder, President of Scientific Advisory Board

NRS Research Director at the Laboratory of Physics and Mechanics of Heterogeneous Environments (PMMH), UMR7636 CNRS, and at ESPCI, Jean-Luc is a specialist in fluid mechanics and flow control.

Jean-Luc worked for 7 years in the Aerodynamics research unit of the Research and Innovation Department of PSA Peugeot-Citroën as the head of a research and innovation project. He joined the CNRS in October 2005 where he developed research programs in the field of flow control, external aerodynamic instabilities, and transition to turbulence and micro-flows. Jean-Luc demonstrated the potential of the acoustic manipulation of particles for metrological applications (micro-PIV).

Jean-Luc also discovered that acoustic streaming in micro-channels can be used beyond the conventional resonance condition in order to create a « sound tweezer » that enables the fine handling of species in suspension.

Read more
Eric Garnier
Strategic Board Member- Independant Chairman

Former Vice President and General Manager of Pall Medical, Eric Garnier joins the Strategic Board as Independent Chairman, playing a key role in accelerating revenue and profit growth while forging new partnerships.

A seasoned executive with experience in Fortune 500 multinationals, he is an operational leader focused on driving sales growth and profitability. He has expertise in the healthcare and industrial markets, with a strong emphasis on sustainability, strategic vision, customer orientation, cost control, and talent management. His multicultural and multifunctional background includes 12 years of expatriation across Europe, Asia, and the USA. Eric Garnier is also a member of the French Institute of Directors (IFA).

Read more
Michel Spagnol
Strategic Board Member

Representing Mifani Invest, Michel Spagnol brings his expertise and network, notably as the former Chairman and CEO of Novasep, to help structure the company.

An experienced Chairperson with a strong background in the chemicals industry, he is skilled in business development, Good Laboratory Practice (GLP), biotechnology, U.S. Food and Drug Administration (FDA) regulations, research and development (R&D), and life sciences.

 

Read more
PTweb
Philippe Tramoy
Strategic Board Member

Philippe Tramoy earned degrees in Biochemistry (MSc) and Genetics & Immunology (MSc) from the University of Burgundy and from the Ecole Normale Supérieure Lyon and later graduated from the IAE Paris Pantheon-Sorbonne (Master of Finance) and HEC Paris (Master in Marketing).

Philippe’s responsibilities have been wide-ranging and included being Project Manager and Business Development Manager in Europe and Israel on the biotechnology market at Rhodia Corporate, Rhodia Chirex, and Rhodia Pharma Solutions.

In 2004, he founded and managed a market and business intelligence company with offices in France, Switzerland and Israel : CBDMT – Market & Business Intelligence. During his career, Philippe developed an extensive network of contacts and core competences including business development, strategy, marketing and finance. Philippe joined Seventure in November 2013. He is a Partner at the Life sciences investments of Quadrivium 1.

Read more

Scientific advisory board

JLAweb
Jean-Luc Aider
Co-founder, President of Scientific Advisory Board

NRS Research Director at the Laboratory of Physics and Mechanics of Heterogeneous Environments (PMMH), UMR7636 CNRS, and at ESPCI, Jean-Luc is a specialist in fluid mechanics and flow control.

Jean-Luc worked for 7 years in the Aerodynamics research unit of the Research and Innovation Department of PSA Peugeot-Citroën as the head of a research and innovation project. He joined the CNRS in October 2005 where he developed research programs in the field of flow control, external aerodynamic instabilities, and transition to turbulence and micro-flows. Jean-Luc demonstrated the potential of the acoustic manipulation of particles for metrological applications (micro-PIV).

Jean-Luc also discovered that acoustic streaming in micro-channels can be used beyond the conventional resonance condition in order to create a « sound tweezer » that enables the fine handling of species in suspension.

Read more
Dr Fermín Sánchez-Guijo Martín
Scientific Advisory Board Member

Fermín Sánchez-Guijo Martín, head of the Cell Therapy Section of the Haematology Department of the University Hospital of Salamanca, full professor of the Department of Medicine of the University of Salamanca and secretary of the Spanish Chronic Myeloid Leukaemia Group of the SEHH, has been elected vice-president of the International Society for Cell and Gene Therapy (ISCT).

The appointment as vice-president-elect will be effective from June 2021 until June 2023, when he will become vice-president of the ISCT until June 2025. This international scientific society brings together all those involved in the development and improvement of cell and gene therapies for clinical use. The outgoing vice-president in June 2021 is Joan García López, director of Research at the Banc de Sang i Teixits de Catalunya and associate of the SEHH.

 

Read more
Mickaël Tanter
Scientific Advisory Board Member

INSERM research director at the Langevin Institute ESPCI Paris, Mickaël developed with his team new therapy techniques and medical imaging, including, for example, non-invasive treatment of brain disorders with transcranial focused ultrasound (Equipex Ultrabrain) or a new brain imaging technique: the »fUltrasound » (functional brain Ultrasound).

This imaging technique based on the study of blood flow can detect changes in cerebral activity. His works led to the creation of a French company, Supersonic Imagine, which markets a scanner that can distinguish the tissue elasticity and variations and identify cancerous tumors. He also founded in 2015 Cardiawave that develops a revolutionary non-invasive medical device to treat a heart condition calledaortic stenosis. Mickaël Tanter is a member of the scientific council of the Ile de France, deputy director of the Langevin Institute, winner of Equipex with his team. He won the grand prize of Medical Research Jean Hamburger of the city of Paris in 2012, co-winner with Mathias Fink, Jacques Souquet and Jeremy Bercoff the Yves Rocard Prize the French Society of Physics 2011, winner of the Léon Brillouin the electricity Company, electronics and information and communications technology (EES) and the Institute of electrical and electronics Engineers (IEEE) in 2010, Montgolfier Prize winner of the Corporation encouragement for the domestic industry in 2010.

Read more
Dr Miquel Lozano
Scientific Advisory Board Member

Miguel Lozano, MD, PhD is Hematologist. He is currently Hemotherapy Section Head at the department of Hemotherapy and Hemostasis of the Clínic University Hospital, and Associate Professor of Medicine at the University of Barcelona, in Barcelona, Spain.

He is also President of the European Society for Hemapheresis, European Regional Director of the ISBT Board and chair of the AABB Press Editorial Board. He has been scientific member of BEST Collaborative since 2002. He is the author or co-author of over 200 papers, monographs and book chapters dealing with topics related with Transfusion Medicine and Hemostasis. He has co-edited books for AABB Press about Globalization in Transfusion Medicine, Blood Component Preparation and Platelet Transfusion Therapy.

Read more
Chaouqi Misbah
Scientific Advisory Board Member

Chaouqi is an exceptional category CNRS research director at the Interdisciplinary Physics laboratory of Joseph FOURNIER University in Grenoble (France).

Chaouqi developed over the year a world expertise on complex fluids with a large focus on blood in vivo and in microchannels (over 200 publications and books).

Read more
Mauricio Hoyos
Co-founder, Scientific Advisory Board Member

CNRS Researcher at the Laboratory of Physics and Mechanics of Heterogeneous Environments (PMMH), UMR7636 CNRS, and at ESPCI, Mauricio is a specialist in dispersed colloidal environments, in separation sciences and in ultrasounds.

Mauricio is the Winner 2014 of the Henri-Langlois price for the quality of his work in the PMMH Laboratory. Mauricio worked for more than 20 years in the field of technical separation of polymer particles and blood cells using force fields (centrifugal, thermal and magnetic). He has been developing ultrasonic separation technologies for biological applications for many years.

Read more